Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.

Valentin JP, Guillon JM, Jenkinson S, Kadambi V, Ravikumar P, Roberts S, Rosenbrier-Ribeiro L, Schmidt F, Armstrong D.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:7-14. doi: 10.1016/j.vascn.2018.07.001. Epub 2018 Jul 17.

PMID:
30030184
2.

Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database.

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, Kadambi VJ.

Toxicol Appl Pharmacol. 2017 Nov 1;334:100-109. doi: 10.1016/j.taap.2017.09.006. Epub 2017 Sep 8.

PMID:
28893587
3.

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.

Csizmadia V, Hales P, Tsu C, Ma J, Chen J, Shah P, Fleming P, Senn JJ, Kadambi VJ, Dick L, Wolenski FS.

Toxicol Res (Camb). 2016 Aug 25;5(6):1619-1628. doi: 10.1039/c6tx00220j. eCollection 2016 Nov 1.

4.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.

Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF.

ACS Med Chem Lett. 2015 Apr 22;6(6):630-4. doi: 10.1021/ml500409n. eCollection 2015 Jun 11.

5.

Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development.

Mangipudy R, Burkhardt J, Kadambi VJ.

Regul Toxicol Pharmacol. 2014 Nov;70(2):439-41. doi: 10.1016/j.yrtph.2014.07.014. Epub 2014 Jul 21.

PMID:
25058855
6.

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ.

Inflamm Bowel Dis. 2012 Nov;18(11):2107-19. doi: 10.1002/ibd.22940. Epub 2012 Mar 14.

PMID:
22419649
7.

Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists.

Blackburn C, LaMarche MJ, Brown J, Che JL, Cullis CA, Lai S, Maguire M, Marsilje T, Geddes B, Govek E, Kadambi V, Doherty C, Dayton B, Brodjian S, Marsh KC, Collins CA, Kym PR.

Bioorg Med Chem Lett. 2006 May 15;16(10):2621-7. Epub 2006 Mar 9.

PMID:
16524729
8.

Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.

Christe M, Jin N, Wang X, Gould KE, Iversen PW, Yu X, Lorenz JN, Kadambi V, Zuckerman SH, Bloem LJ.

J Mol Cell Cardiol. 2004 Sep;37(3):705-15.

PMID:
15350844
9.

Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins.

Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, Stagliano N, Fairchild-Huntress V, Xu J, Lorenz JN, Kadambi V, Berul CI, Breitbart RE.

J Mol Cell Cardiol. 2003 Sep;35(9):1043-53.

PMID:
12967627
10.

Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy.

Dash R, Schmidt AG, Pathak A, Gerst MJ, Biniakiewicz D, Kadambi VJ, Hoit BD, Abraham WT, Kranias EG.

Cardiovasc Res. 2003 Mar;57(3):704-14.

PMID:
12618232
11.

Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis.

Kiriazis H, Sato Y, Kadambi VJ, Schmidt AG, Gerst MJ, Hoit BD, Kranias EG.

Cardiovasc Res. 2002 Feb 1;53(2):372-81.

PMID:
11827688

Supplemental Content

Loading ...
Support Center